Moderna Enters Gene Editing Market with Metagenomi Collaboration
Moderna jumped into the spotlight during the COVID-19 after it became one of the first companies to produce an effective vaccine using mRNA technology. This was Moderna’s first commercial product. Currently, most of their pipeline focuses on vaccine development, with their second most advanced product being a vaccine for Cytomegalovirus (CMV), currently in Phase 3 clinical trials. CMV is one of the leading causes of childhood hearing loss. Their pipeline also includes vaccines for Zika, influenza, and other viruses.
However, their mRNA platform can be used to develop therapies beyond vaccines. For example, they are using their technology to develop instructions for cells to produce antibodies against the Chikungunya virus and autoimmune disorders. Due to the versatile nature of their mRNA platform, Moderna can expand to new markets.